FoRx Therapeutics is a privately held clinical-stage biotechnology company developing precision therapeutics that target the DNA Damage Response (DDR) in treatment-resistant cancers.
The company’s lead product candidate, FORX-428, is an oral small-molecule PARG inhibitor in Phase 1 development for advanced solid tumors, aimed at treating cancers resistant to PARP inhibitors.
Leadership & Board
Current Number of Employees34
Current LinkedIn Followers7,332
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$50M
Total Amount Raised$50M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$50M
Latest Funding Amount$50M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
FoRx Therapeutics had 34 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
34Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
FoRx Therapeutics had 7,332 followers as of September 28, 2026. The number of followers increased by 21 (0.29%) week-over-week.
7,332Latest Followers Count
21(0.29%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.